Short-term intraocular pressure trends in high risk patients following intravitreal Ranibizumab (Lucentis) injections for Wet Age Related Macular Degeneration - Is there a role for systemic Acetazolamide (Diamox) in those with glaucoma? - LIEPS - Lucentis Injection Eye Pressure Study

York Teaching Hospital NHS Foundation Trust0 个研究点目标入组 24 人开始时间: 2010年12月6日最近更新: 2012年11月5日

适应症

试验速览

暂无简介。

•The sample group will include glaucoma and glaucoma suspect patients undergoing intravitreal injections for neovascular (wet) AMD at York Hospital.
•1.Patients with neovascular (wet) AMD requiring Lucentis injections
•2.Glaucoma or Glaucoma suspect
•3.Written informed consent
•4. Baseline pre injection Intraocular Pressure of less than 30 mmHg
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 0
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 24

•1.Baseline pre-injection IOP of 30 mmHg or higher
•2.Unable to give written informed consent
•3.Known allergy to sulphur containing drugs or acetazolamide
•4. 18 years or younger
•5. Marked kidney or liver disease/dysfunction
•6. Supra-renal gland failure
•7. Hypercholrcmic adcidosis
•8. Hepatic cirrhosis
•9. Pregnancy and pre-menopausal women
•10. Concomitant use of other oral carbonic anhydrase inhibitors apart from acetazolamide

发起方